Results 21 to 30 of about 14,850 (194)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Cardiovascular Diabetology, 2023
Background This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation.
Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink   +10 more
doaj   +1 more source

Results of the DAPA-CKD trial and their impact on clinical practice

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Chronic kidney disease (CKD) is a growing medical and social problem in the world. Data from population base stu­dies demonstrate an increase in the prevalence of CKD and mortality. One of the causes is an increase in the number of patients with diabetes.
O.V. Bilchenko
doaj   +1 more source

Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

Heliyon, 2022
Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from “glomerulocentric” to “tubule centric ...
Noriko Uehara-Watanabe, Natsuko Okuno-Ozeki, Itaru Nakamura, Tomohiro Nakata, Kunihiro Nakai, Aya Yagi-Tomita, Tomoharu Ida, Noriyuki Yamashita, Michitsugu Kamezaki, Yuhei Kirita, Satoaki Matoba, Keiichi Tamagaki, Tetsuro Kusaba   +12 more
doaj   +1 more source

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Frontiers in Pharmacology, 2022
Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood ...
Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing, Peter Rossing   +8 more
doaj   +1 more source

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Cardiovascular Diabetology, 2022
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying
Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp, Richard G. IJzerman   +7 more
doaj   +1 more source

Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become an important component of standard treatment for type 2 diabetes because of its ...
Xuehua Liu, Tian Zhang, Rong Fu, Dan Liu, Jingyi Zhang, Qing Hu, Guangyao Song, Luping Ren   +7 more
doaj   +1 more source

Production, use, transfer of prodrug substances, and direct or indirect infringement of the patent: Focusing on the dapagliflozin formate case

Journal of Intellectual Property
This study explored whether the utilization of dapagliflozin formate, a dapagliflozin prodrug, constitutes direct (including literal infringement and infringement under the doctrine of equivalents) and indirect infringement, against a patent covering a ...
Kwanshik Kim
doaj   +1 more source

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors

Frontiers in Pharmacology, 2021
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment.
Jong-Mi Seong, Jong Joo Kim, Hae Jin Kim, Hyun Soon Sohn   +3 more
doaj   +1 more source

Ultrasound‐Triggered Nanobubbles for Endothelial‐Targeted Drug Delivery in the Detection and Treatment of Doxorubicin‐Induced Cardiotoxicity

Advanced Healthcare Materials, EarlyView.
The DA/VTP‐NBs selectively recognized cardiac ECs damaged by DIC and achieved cell‐level targeted imaging. Then US‐triggered controlled release successfully enabled the release of DAPA within the DA/VTP‐NBs at the site of injury. This precise on‐demand drug release approach amplifies a series of localized therapeutic effects through the mtDNA‐mediated ...
Jun Zhang, Yi Ling, Xin Li, Deng Liu, Li Dong, Xuemei Chen, Yingxin Sun, Yongning Shang, Yanli Guo   +8 more
wiley   +1 more source

PAF Triggered Pyroptotic NETosis Aggravates Myocardial Ischemia/Reperfusion Injury

Advanced Science, EarlyView.
Platelet activating factor (PAF) secreted by cardiomyocytes during MI/R, drives NETs formation and subsequent NETosis. PAF/NETosis signaling activation is an initiative and causal factor in driving MI/R injury. This study identifies dapagliflozin as a potent NETosis inhibitor, and demonstrates that manipulating PAF‐NETosis signal by dapagliflozin or ...
Jiawei Wu, Shule Zhang, Ruofan Du, Lina Kang, Guodong Zhao, Xue Bao, Haochi Yang, Ziqing Xie, Tianyu He, Huiyong Sun, Haiping Hao, Lijuan Cao   +11 more
wiley   +1 more source